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Use of Sildenafil to Facilitate Weaning From Inhaled Nitric Oxide in Children With 
Pulmonary Hypertension Following Surgery for Congenital Heart Disease  
Jaclyn E. Lee, Simon C. Hillier, Chad A. Knoderer 
Abstract 
Pulmonary hypertension frequently complicates the postoperative management of patients after 
congenital cardiac surgery. Inhaled nitric oxide is an effective treatment option, but rebound pulmonary 
hypertension can occur upon its withdrawal. Sildenafil may facilitate its withdrawal by restoring cyclic 
guanosine monophosphate availability via phosphodiesterase-5 inhibition. The purpose of this study was 
to evaluate the use of sildenafil in facilitating weaning from inhaled nitric oxide after congenital cardiac 
surgery in patients who had previously failed weaning, and to compare the effects of sildenafil on 
pulmonary and systemic hemodynamics. Children who received sildenafil after cardiovascular surgery 
during a 23-month period at Riley Hospital for Children were identified. Medical records were 
retrospectively reviewed to determine sildenafil and nitric oxide dosing, pulmonary and systemic blood 
pressures, and adverse effects. Oral sildenafil was administered to 7 children who had failed attempts at 
inhaled nitric oxide weaning. Inhaled nitric oxide was weaned from 29.8 ± 5.9 ppm prior to sildenafil 
initiation to 12.2 ± 3.4 ppm (mean ± SE; P = .024) in the 24 hours after sildenafil. Mean pulmonary artery 
and systemic arterial pressure were unchanged from baseline when measured 1 hour after sildenafil 
dosing (mean pulmonary artery pressure, 29 ± 1 to 27 ± 0.7 mm Hg, P = .066; mean systemic arterial 
pressure, 56 ± 1.2 to 54 ± 1.2 mm Hg, P = .202). Sildenafil may facilitate withdrawal of inhaled nitric 
oxide and prevent rebound pulmonary hypertension in patients previously failing inhaled nitric oxide 
weaning attempts. 
Pulmonary hypertension (PHTN) is an important cause of morbidity and mortality in pediatric 
patients with congenital heart disease. Congenital heart defects that are associated with 
significant increases in pulmonary blood flow, pulmonary venous obstruction, and cyanosis are 
most likely to predispose to postoperative PHTN.
1,2
 Surgery for congenital heart disease usually 
requires cardiopulmonary bypass (CPB), which is associated with temporary pulmonary 
endothelial dysfunction and suppression of endogenous nitric oxide (NO) production, further 
predisposing to PHTN. Furthermore, the systemic inflammatory response to CPB is associated 
with increases in endothelin production, which also contributes to elevations in pulmonary 
vascular tone.
3-5
 Children with PHTN following CPB require significantly longer ventilatory 
support and intensive care stays.
6
 Patients who undergo correction of total anomalous pulmonary 
venous connection (TAPVC), transposition of the great arteries (TGA), ventricular septal defect 
(VSD), and atrioventricular canal (AVC) are at particularly increased risk for postoperative 
pulmonary hypertensive events and subsequent morbidity and mortality.
7 
 
There are a number of pharmacologic treatment options for PHTN in children after cardiac 
surgery. In most cases, inhaled NO (iNO) effectively reduces pulmonary artery pressures (PAP) 
and reduces the incidence of postoperative pulmonary hypertensive crises.
8-10
 Inhaled nitric 
oxide causes selective vasodilation in the pulmonary circulation by increasing smooth muscle 
intracellular cyclic guanosine monophosphate (cGMP) availability. However, the effect of cGMP 
is short-lived because it is promptly degraded by local phosphodiesterases. Sildenafil is a 
phosphodiesterase (PDE) inhibitor with high selectivity against isoform 5, the predominant PDE 
isoform in the lung responsible for the breakdown of cGMP.
11
 Sildenafil would be predicted to 
enhance and prolong the effects of cGMP in pulmonary circulation, causing significant PAP 
reduction with minimal systemic effects.
12
 Despite widespread adoption of sildenafil as an 
adjunct to or in place of iNO, there are limited data regarding dosing and efficacy. Furthermore, 
the use for PHTN in children remains off-label and is not approved by the Food and Drug 
Administration (FDA). 
The primary objective of this retrospective study was to evaluate the use of sildenafil in 
facilitating weaning from iNO in patients who had previously failed iNO weaning after 
congenital cardiac surgery at a single tertiary care pediatric center. A secondary objective was to 
compare the effect of sildenafil on pulmonary and systemic hemodynamics. We sought to test 2 
hypotheses. First, sildenafil administration would be associated with a reduction in iNO 
requirements as determined by comparing the mean iNO doses in the 24-hour periods before and 
after sildenafil administration in patients who had previously failed attempts to wean iNO. 
Second, sildenafil would preferentially reduce PAP versus systemic arterial pressures (SAP).  
Methods 
This retrospective study was conducted after approval from the institutional human subjects 
review board. All patients undergoing cardiovascular surgery and receiving sildenafil during a 
23-month period between January 2003 and November 2004 at Riley Hospital for Children, 
Indianapolis, Ind, were eligible for inclusion in the study. This time frame represented the initial 
period of sildenafil use at our hospital. A pharmacy computer-generated list was used to identify 
patients meeting these inclusion criteria. Patients older than 18 years were excluded. Patient 
cases in which the complete medical chart was unavailable for review after 3 requests from the 
hospital's medical records department were excluded. Examination of all patient charts meeting 
inclusion criteria was performed to identify those patients who had previously failed iNO 
weaning and patients who had both PAP and SAP data from before and following sildenafil 
administration. 
Table 1.  Inhaled Nitric Oxide Weaning Protocol  
iNO Dose    
Range at Wean  Dose Increment  Wean Frequency,  
Initiation, ppm  Decrease, ppm  Hours  
20 – 40  5  1-2  
10 – 20  2 1-2  
2 – 10  1  1-2  
0 – 2  0.5  1-2  
NOTES: iNO = inhaled nitric oxide; ppm = parts per million.  
The iNO weaning protocol used during the study period is described in Table 1. Failure to 
tolerate weaning was defined as a significant decrease in cardiac output (as reflected by declining 
blood pressure, declining mixed venous oxygen saturation, increasing base deficit or lactate, or 
worsening peripheral perfusion) and/or increasing PHTN or pulmonary hypertensive crises 
(typical clinical manifestations include declining arterial saturation, sustained increased PAP 
above previous values, and increasing arterial carbon dioxide). It should be noted that transient 
(<30 minutes) hemodynamically insignificant increases in PAP frequently occur in association 
with downward adjustments of the iNO doseand do not necessarily reflect weaning failure.  
 
 Demographic data collected included patient age, weight, gender, and underlying congenital 
heart defect. Additional data included sildenafil and iNO dosing and documentation of adverse 
effects. Mean iNO doses were calculated for the 24-hour periods preceding and following the 
first administration of sildenafil. The time to cessation of iNO administration after sildenafil 
initiation was also determined. Pulmonary and systemic blood pressures were retrieved from the 
nursing flow sheet and recorded at baseline (prior to sildenafil dosing) and every hour for up to 4 
hours after each sildenafil dose. Sildenafil was administered to all patients as a 2 mg/mL liquid 
formulation compounded by the hospital pharmacy. 
Hemodynamic data were compared using analysis of variance (ANOVA) to determine if 
sildenafil administration was associated with hemodynamic change from control levels. Mean 
24-hour iNO dose data were compared using a paired-sample t test to determine if sildenafil 
administration was associated with significant decreases in iNO dosing. P values of less than .05 
were considered to be statistically significant. Statistical analyses were conducted using 
Statistical Package for Social Sciences version 14.0 (SPSS Inc, Chicago, Ill).  
Results 
Fifty-four children received oral sildenafil after cardiac surgery during the 23-month study 
period. Complete medical records were available for review in 35 patients. Nineteen patients 
received iNO therapy, with 7 patients previously failing iNO weaning. Patient characteristics 
(including congenital heart defects) of these 7 patients are displayed in Table 2. 
Patients (n = 7) ranged in age from 3 days to 21 months (median, 12 months) and weighed from 
3.0 kg to 12.7 kg (mean, 5.7 kg). The average initial and maximal doses of sildenafil were 0.3 
mg/kg (SD, 0.088 mg/kg; range, 0.22-0.47 mg/kg), and was administered 4 times daily either 
orally or via nasogastric tube. Sildenafil was continued for an average of 28 days. 
In these 7 patients, iNO was weaned from 29.8 +- 5.9 parts per million (ppm) prior to sildenafil 
initiation to 12.2 +- 3.4 ppm (mean +- SE; P = .024) in the 24 hours after sildenafil initiation. 
Table 2. Characteristics and iNO Data for Children Who Failed iNO Weaning 
    Days of iNO 
Therapy 
Prior to 
Sildenafil 
Adminsitration 
 
  
Initial iNO 
Dose, ppm 
Maximum 
iNO 
Dose, 
ppm 
Total 
iNO 
Duration, 
Days 
Patient Age/Gender Defect 
11 mo/F DORV 20 80 20 23 
1 wk /M DTGV 40 80 6 7 
1 mo/F DTGV 10 60 28 37 
4 mo/M DTGV, VSD 20 20 5 6 
21 mo/M 
HLHS, s/p Hemi-
Fontan 
40 40 9 10 
4 d/F PA, ASD 20 40 10 22 
3 d/M TAPVC, ASD 20 40 10 17 
NOTES: iNO =  inhaled nitric oxide; ppm = parts per million; F = female; DORV = double outlet right ventricle; 
DTGV = d-transposition of the great vessels; VSD = ventricular septal defect; HLHS = hypoplastic left heart 
syndrome; s/p = status post;  PA = pulmonary atresia; ASD = atrial septal defect; TAPVC = total anomalous 
pulmonary venous connection. 
Rebound PHTN was not observed in these patients. The mean time to discontinuation of iNO 
after sildenafil initiation was 4.4 days. 
Mean pulmonary artery pressure (MPAP) and mean systemic arterial pressure (MSAP) were 
evaluated in 10 patients (of the initial group of 35) who had both pulmonary artery and arterial 
hemodynamic cathers placed to determine if sildenafil would preferentially reduce PAP versus 
SAP. From baseline to 1 hour after sildenafil dosing (mean dose, 0.33 mg/kg; range, 0.1-0.62 
mg/kg), the MPAP decreased from 29 +- 1 to 27 +- 0.7 mm Hg (mean +- SE; P = .066), and 
MSAP decreased from 56 +- 1.2 to 54 +- 1.2 mm Hg (mean +- SE; P = .202). Mean pulmonary 
artery pressure (P = .272) and MSAP (P = .692) did not differ from control levels (prior to 
sildenafil initation) when compared to any of the hourly intervals after sildenafil dosing (Figure 
1). 
One patient out of the group of 35 experienced systemic hypotension requiring sildenafil 
discontinuation (this patient had not failed iNO weaning and is not represented in the group of 
7). No other sildenafil-associated adverse effects were observed. 
 
Figure 1 Mean pulmonary artery and mean systemic arterial 
pressure at baseline and after sildenafil administration (n = 10). 
∆, mean systemic arterial pressure (P = .692); □, mean pulmonary 
artery pressure (P = .272) 
Discussion 
Sildenafil appears to be a useful adjunct for the treatment of PHTN after surgery for congenital 
heart disease. Our data show that sildenafil administration resulted in significantly decreased 
iNO dose 332 (Figure 1). Mean pulmonary artery and mean systemic arterial pressure at baseline 
and after sildenafil administration (n = 10). ^, mean systemic arterial pressure (P = .692); #, 
mean pulmonary artery pressure (P = .272) requirements and facilitated iNO weaning in patients 
previously failing weaning attempts. Sildenafil administration appears safe in our patient 
population. Discontinuation of sildenafil due to systemic hypotension is uncommon in our 
experience, occurring in 3% (1/35) of cases. However, we continue to be cautious to avoid the 
administration of sildenafil in patients whom we suspect are hypovolemic.  
The oral dosing used in our setting was extrapolated from previous published experiences. Our 
starting doses of sildenafil were similar to those used in previous reports.
13-16
 However, in the 
immediate postoperative period, drug absorption may be unpredictable because of alterations in 
gastric motility and perfusion. Sildenafil dosing was not increased in our 7 patients previously 
failing iNO weaning. Higher doses of sildenafil may be required in the postoperative setting to 
achieve a decrease in PAP when compared to the dose required to prevent increases in 
pulmonary pressure during iNO weaning. The intravenous preparation is not yet available in the 
United States, but it is likely that intravenous dosing of sildenafil will avoid the issues related to 
erratic oral pharmacokinetics. 
Inhaled nitric oxide is the standard pharmacologic therapy for postoperative PHTN at our 
institution and is generally used in conjunction with controlled moderate hyperventilation, 
sedation, and paralysis. However, rebound PHTN can complicate the withdrawal of iNO. 
Exogenous NO is associated with down-regulation of endothelial NO synthase.17-19 Inhaled NO 
presdisposes patients to rebound PHTN by increasing levels of endothelin-1, a potent pulmonary 
vasoconstrictor.
20
 Sildenafil has a high selectivity for PDE-5, thus increasing endothelial pro- 
duction of cGMP and ultimately facilitating withdrawal of iNO in patients with PHTN. 
There are few clinical studies evaluating the efficacy of sildenafil in children with congenital 
heart disease (Table 3). Erickson and colleagues demonstrated in 5 children that sildenafil 
administration facilitated discontinuation of iNO 4 to 6 hours after oral administration.15 
Namachivayam et al showed that 1 dose of oral sildenafil (0.4 mg/kg, rounded to nearest 1 mg) 
successfully prevented rebound PHTN in 15 children who were weaned from iNO.16 In this 
study, rebound PHTN occurred in 10 of 14 placebotreated patients. Namachivayam and 
colleagues reported success in facilitating withdrawal from iNO but specifically excluded 
patients who had previously failed iNO weaning attempts.16 However, 4 of the placebo-treated 
patients subsequently failed to wean from iNO.
16
 In contrast, our data demonstrates that the 
addition of oral sildenafil aids in the withdrawal of iNO and prevents rebound PHTN in children 
who had previously failed iNO weaning attempts. 
There are additional case reports that describe the effectiveness of oral sildenafil to facilitate iNO 
weaning in children after cardiac surgery.
13,14,21,22
 Results of our study are consistent with these 
previously reported cases. Sildenafil was used in a 9-monthold with congenital mitral stenosis 
and allowed for the weaning of NO and prevented further pulmonary hypertensive episodes.13 
Atz and Wessel also reported that sildenafil administration facilitated withdrawal of NO without 
rebound PHTN in 3 patients with PHTN after cardiac surgery.
14 
Other clinical investigations demonstrate the effectiveness of sildenafil in children with PHTN. 
While currently not available in the United States, intravenous sildenafil is associated with a 
significant decrease in PAP in both children undergoing cardiac catheterization and in those after 
cardiac surgery.
23 
  
 
Stocker and colleagues demonstrate that intravenous sildenafil enhances the pulmonary 
vasodilatory effects of iNO, but significantly decreases oxygenation.
24
 Our study of oral 
sildenafil did not reveal similar effects on PAP and did not adequately assess oxygenation 
changes. 
Our study did not demonstrate that that sildenafil would preferentially reduce PAP versus SAP. 
The lack of significant effect observed on PA pressures in our study may be due to a number of 
reasons. The most likely reason is the simultaneous attempts to wean iNO. However, our data is 
similar to those of Namachivayam and colleagues who did not find significant changes in PAP 
after sildenafil dosing.
16
 Additionally, a steady-state serum concentration of sildenafil may not 
have been achieved when the PAP were evaluated. 
Limitations 
Limitations of our study include the retrospective design, absence of a control group, and small 
sample size. These limit the ability of this study to determine if the ability to wean iNO was an 
effect of sildenafil administration or time after surgery. Sildenafil dosing was extrapolated from 
previous published experiences, but ultimately was left to the discretion of the primary 
physician, which may account for the observed variability in initial dosing or upward titra- tion. 
A larger sampling may allow for subgroup analysis of the effects of sildenafil in patients with 
congenital heart defects who are at greatest risk for postoperative PHTN. Although sildenafil was 
safely used in our population, because of the retrospective design, we were unable to adequately 
evaluate potential complications of sildenafil administration such as intrapulmonary shunting or 
worsening of oxygenation that have been reported by other investigators.
16 
Conclusion  
Sildenafil may facilitate the withdrawal of iNO therapy while preventing rebound PHTN in 
pediatric patients after surgery for congenital heart disease 334 who have previously failed to 
wean from iNO. Only 1 patient in our study required discontinuation of sildenafil because of 
systemic hypotension. Further con- trolled prospective analyses are warranted to determine if 
sildenafil, or other PDE-5 antagonists, may be routinely indicated to facilitate weaning from, and 
thus limiting exposure to, iNO and to test the hypothesis that there is no preferential effect of 
sildenafil on systemic versus the pulmonary circulation. 
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